within Pharmacolibrary.Drugs.ATC.J;

model J06BB11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0035 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.06 / 1000000,
    adminCount     = 1,
    Vd             = 8e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Hepatitis A immunoglobulin (human) is a purified antibody preparation derived from pooled human plasma containing high titers of hepatitis A antibodies. It is used for prophylaxis against hepatitis A virus infection, particularly in post-exposure cases or for travelers to endemic regions. It is approved and in use for these indications as a passive immunization product.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers receiving a single intramuscular injection of immunoglobulin.</p><h4>References</h4><ol><li><p>Kankam, M, et al., &amp; Vilardell, D (2020). Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects. <i>Advances in therapy</i> 37(5) 2373–2389. DOI:<a href=&quot;https://doi.org/10.1007/s12325-020-01327-9&quot;>10.1007/s12325-020-01327-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32301062/&quot;>https://pubmed.ncbi.nlm.nih.gov/32301062</a></p></li><li><p>Young, MK, et al., &amp; Cripps, AW (2020). Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure. <i>Expert opinion on drug metabolism &amp; toxicology</i> 16(7) 641–644. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2020.1763303&quot;>10.1080/17425255.2020.1763303</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32362179/&quot;>https://pubmed.ncbi.nlm.nih.gov/32362179</a></p></li><li><p>Ragni, MV, et al., &amp; Krause, DS (2000). Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. <i>Haemophilia : the official journal of the World Federation of Hemophilia</i> 6(2) 98–103. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2516.2000.00386.x&quot;>10.1046/j.1365-2516.2000.00386.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10781196/&quot;>https://pubmed.ncbi.nlm.nih.gov/10781196</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J06BB11;
